Eteplirsen
Brand name: Exondys-51
Rank #488 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$14.4M
Total Cost
192
Total Claims
$14.4M
Total Cost
8
Prescribers
$75K
Cost per Claim
0
Beneficiaries
192
30-Day Fills
$1.8M
Avg Cost/Provider
24
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$14.4M of $275.65B
Top Prescribers by Cost
Top 8 prescribers of $14.4M total
🔎 Data Overview
At $74,847 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.
Average cost of $1,796,317 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Eteplirsen
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Debra Guntrum | Nurse Practitioner | Rochester, NY | 34 | $3.1M |
| 2 | Erin Neil Knierbein | Pediatric Medicine | Ann Arbor, MI | 17 | $2.2M |
| 3 | Diana Mnatsakanova | Neurology | Chicago, IL | 26 | $1.9M |
| 4 | Laurence Walsh | Neurology | Indianapolis, IN | 22 | $1.7M |
| 5 | Michael Isfort | Neurology | Columbus, OH | 22 | $1.6M |
| 6 | Cynthia Bodkin | Neurology | Indianapolis, IN | 16 | $1.5M |
| 7 | Amanda Witt | Physical Medicine and Rehabilitation | Jackson, MS | 31 | $1.4M |
| 8 | Senda Ajroud-Driss | Neuropsychiatry | Chicago, IL | 24 | $1.1M |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 485 | Dihydroergotamine Mesylate (Dihydroergotamine Mesylate) | $14.4M | 6,855 |
| 486 | Clotrimazole/Betamethasone Dip (Clotrimazole-Betamethasone) | $14.4M | 503,015 |
| 487 | Verapamil Hcl (Verapamil Er) | $14.4M | 329,950 |
| 488 | Eteplirsen (Exondys-51) | $14.4M | 192 |
| 489 | Colesevelam Hcl (Colesevelam Hcl) | $14.3M | 50,268 |
| 490 | Bexarotene (Bexarotene) | $14.2M | 1,613 |
| 491 | Ozanimod Hydrochloride (Zeposia) | $14.2M | 1,535 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology